HCW Biologics (NASDAQ:HCWB) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of HCW Biologics (NASDAQ:HCWB) from a hold rating to a sell rating in a report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $30.00.

HCW Biologics Stock Up 4.6%

HCWB stock opened at $1.60 on Friday. HCW Biologics has a 52-week low of $1.50 and a 52-week high of $27.57. The stock has a market cap of $3.58 million, a price-to-earnings ratio of -0.06 and a beta of 2.41. The business has a fifty day moving average of $2.45 and a two-hundred day moving average of $4.18.

HCW Biologics (NASDAQ:HCWB) last announced its quarterly earnings results on Friday, August 14th. The company reported ($11.58) EPS for the quarter, missing the consensus estimate of ($1.98) by ($9.60). The business had revenue of $0.14 million during the quarter, compared to analyst estimates of $0.14 million. HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%.

HCW Biologics Company Profile

HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company developing immunotherapies for diseases associated with chronic inflammation, including inflammation linked to aging and age-related conditions. The company’s research is focused on modulating the immune system to address “inflammaging,” a persistent, low-grade inflammatory state that may contribute to multiple diseases.

HCW Biologics’ product candidates are based on its proprietary immunotherapy platform, which is designed to combine immune-stimulating and inflammation-modulating activities in a single biologic.